# Church & Dwight Co Inc: financial statements, quarterly CHD · NYSE · CIK 313927 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/chd.md) · [Financials](/companies/chd/financials.md) · [Filings](/companies/chd/filings.md) · [Insiders](/companies/chd/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/chd/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1,456](/filings/0000950170-24-120026.md) | [1,528 d](/filings/0001193125-26-048139.md) | [1,503](/filings/0000950170-25-061624.md) | [1,511](/filings/0000950170-25-101235.md) | [1,511](/filings/0001193125-25-260515.md) | [1,582 d](/filings/0001193125-26-048139.md) | [1,467](/filings/0001193125-26-200630.md) | [1,506](/filings/0001193125-26-327567.md) | [1,586](/filings/0001193125-25-260515.md) | [1,644 d](/filings/0001193125-26-048139.md) | [1,469](/filings/0001193125-26-200630.md) | [1,530](/filings/0001193125-26-327567.md) | | Cost of revenue | $m | [810](/filings/0000950170-24-120026.md) | [847 d](/filings/0001193125-26-048139.md) | [816](/filings/0000950170-25-061624.md) | [799](/filings/0000950170-25-101235.md) | [828](/filings/0001193125-25-260515.md) | [874 d](/filings/0001193125-26-048139.md) | [808](/filings/0001193125-26-200630.md) | [859](/filings/0001193125-26-327567.md) | [871](/filings/0001193125-25-260515.md) | [890 d](/filings/0001193125-26-048139.md) | [788](/filings/0001193125-26-200630.md) | [836](/filings/0001193125-26-327567.md) | | Gross profit | $m | [646](/filings/0000950170-24-120026.md) | [681 d](/filings/0001193125-26-048139.md) | [687](/filings/0000950170-25-061624.md) | [712](/filings/0000950170-25-101235.md) | [683](/filings/0001193125-25-260515.md) | [708 d](/filings/0001193125-26-048139.md) | [660](/filings/0001193125-26-200630.md) | [647](/filings/0001193125-26-327567.md) | [714](/filings/0001193125-25-260515.md) | [754 d](/filings/0001193125-26-048139.md) | [681](/filings/0001193125-26-200630.md) | [694](/filings/0001193125-26-327567.md) | | Research and development | $m | [30.3](/filings/0000950170-24-120026.md) | [35.2 d](/filings/0001193125-26-048139.md) | [30.1](/filings/0000950170-25-061624.md) | [33.0](/filings/0000950170-25-101235.md) | [36.0](/filings/0001193125-25-260515.md) | [40.6 d](/filings/0001193125-26-048139.md) | [32.8](/filings/0001193125-26-200630.md) | [35.8](/filings/0001193125-26-327567.md) | [36.2](/filings/0001193125-25-260515.md) | [40.8 d](/filings/0001193125-26-048139.md) | [31.6](/filings/0001193125-26-200630.md) | [33.9](/filings/0001193125-26-327567.md) | | Selling, general and administrative | $m | [223](/filings/0000950170-24-120026.md) | [246 d](/filings/0001193125-26-048139.md) | [230](/filings/0000950170-25-061624.md) | [223](/filings/0000950170-25-101235.md) | [232](/filings/0001193125-25-260515.md) | [243 d](/filings/0001193125-26-048139.md) | [228](/filings/0001193125-26-200630.md) | [228](/filings/0001193125-26-327567.md) | [257](/filings/0001193125-25-260515.md) | [276 d](/filings/0001193125-26-048139.md) | [251](/filings/0001193125-26-200630.md) | [252](/filings/0001193125-26-327567.md) | | Operating income | $m | [256](/filings/0000950170-24-120026.md) | [216 d](/filings/0001193125-26-048139.md) | [305](/filings/0000950170-25-061624.md) | [337](/filings/0000950170-25-101235.md) | [(91.5)](/filings/0001193125-25-260515.md) | [257 d](/filings/0001193125-26-048139.md) | [295](/filings/0001193125-26-200630.md) | [262](/filings/0001193125-26-327567.md) | [255](/filings/0001193125-25-260515.md) | [266 d](/filings/0001193125-26-048139.md) | [291](/filings/0001193125-26-200630.md) | [276](/filings/0001193125-26-327567.md) | | Interest expense | $m | [27.2](/filings/0000950170-24-120026.md) | [27.0 d](/filings/0001193125-26-048139.md) | [25.0](/filings/0000950170-25-061624.md) | [23.2](/filings/0000950170-25-101235.md) | [23.4](/filings/0001193125-25-260515.md) | [23.4 d](/filings/0001193125-26-048139.md) | [23.3](/filings/0001193125-26-200630.md) | [23.5](/filings/0001193125-26-327567.md) | [23.8](/filings/0001193125-25-260515.md) | [24.6 d](/filings/0001193125-26-048139.md) | [24.0](/filings/0001193125-26-200630.md) | [24.2](/filings/0001193125-26-327567.md) | | Income tax | $m | [56.5](/filings/0000950170-24-120026.md) | [41.5 d](/filings/0001193125-26-048139.md) | [56.4](/filings/0000950170-25-061624.md) | [77.0](/filings/0000950170-25-101235.md) | [(26.3)](/filings/0001193125-25-260515.md) | [63.9 d](/filings/0001193125-26-048139.md) | [62.0](/filings/0001193125-26-200630.md) | [59.5](/filings/0001193125-26-327567.md) | [54.0](/filings/0001193125-25-260515.md) | [44.6 d](/filings/0001193125-26-048139.md) | [56.3](/filings/0001193125-26-200630.md) | [53.1](/filings/0001193125-26-327567.md) | | Net income | $m | [178](/filings/0000950170-24-120026.md) | [154 d](/filings/0001193125-26-048139.md) | [228](/filings/0001193125-25-260515.md) | [244](/filings/0001193125-25-260515.md) | [(75.1)](/filings/0001193125-25-260515.md) | [189 d](/filings/0001193125-26-048139.md) | [220](/filings/0001193125-26-327567.md) | [191](/filings/0001193125-26-327567.md) | [182](/filings/0001193125-25-260515.md) | [144 d](/filings/0001193125-26-048139.md) | [216](/filings/0001193125-26-327567.md) | [203](/filings/0001193125-26-327567.md) | | Diluted EPS | $ per share | [0.71](/filings/0000950170-24-120026.md) | not reported | [0.93](/filings/0000950170-25-061624.md) | [0.99](/filings/0000950170-25-101235.md) | [(0.31)](/filings/0001193125-25-260515.md) | not reported | [0.89](/filings/0001193125-26-200630.md) | [0.78](/filings/0001193125-26-327567.md) | [0.75](/filings/0001193125-25-260515.md) | not reported | [0.91](/filings/0001193125-26-200630.md) | [0.85](/filings/0001193125-26-327567.md) | | Basic EPS | $ per share | [0.72](/filings/0000950170-24-120026.md) | not reported | [0.94](/filings/0000950170-25-061624.md) | [1.00](/filings/0000950170-25-101235.md) | [(0.31)](/filings/0001193125-25-260515.md) | not reported | [0.90](/filings/0001193125-26-200630.md) | [0.78](/filings/0001193125-26-327567.md) | [0.75](/filings/0001193125-25-260515.md) | not reported | [0.91](/filings/0001193125-26-200630.md) | [0.86](/filings/0001193125-26-327567.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [573](/filings/0000950170-23-058681.md) | [345](/filings/0000950170-25-019801.md) | [350](/filings/0000950170-24-051879.md) | [492](/filings/0000950170-24-090144.md) | [752](/filings/0000950170-24-120026.md) | [964](/filings/0001193125-26-048139.md) | [1,075](/filings/0000950170-25-061624.md) | [923](/filings/0000950170-25-101235.md) | [305](/filings/0001193125-25-260515.md) | [409](/filings/0001193125-26-327567.md) | [503](/filings/0001193125-26-200630.md) | [255](/filings/0001193125-26-327567.md) | | Current assets | $m | [1,745](/filings/0000950170-23-058681.md) | [1,530](/filings/0000950170-25-019801.md) | [1,534](/filings/0000950170-24-051879.md) | [1,755](/filings/0000950170-24-090144.md) | [2,017](/filings/0000950170-24-120026.md) | [2,241](/filings/0001193125-26-048139.md) | [2,359](/filings/0000950170-25-061624.md) | [2,230](/filings/0000950170-25-101235.md) | [1,631](/filings/0001193125-25-260515.md) | [1,597](/filings/0001193125-26-327567.md) | [1,721](/filings/0001193125-26-200630.md) | [1,522](/filings/0001193125-26-327567.md) | | Total assets | $m | [8,702](/filings/0000950170-23-058681.md) | [8,569](/filings/0000950170-25-019801.md) | [8,562](/filings/0000950170-24-051879.md) | [8,762](/filings/0000950170-24-090144.md) | [8,666](/filings/0000950170-24-120026.md) | [8,883](/filings/0001193125-26-048139.md) | [8,956](/filings/0000950170-25-061624.md) | [8,788](/filings/0000950170-25-101235.md) | [9,144](/filings/0001193125-25-260515.md) | [8,912](/filings/0001193125-26-327567.md) | [9,007](/filings/0001193125-26-200630.md) | [9,106](/filings/0001193125-26-327567.md) | | Current liabilities | $m | [1,188](/filings/0000950170-23-058681.md) | [1,422](/filings/0000950170-25-019801.md) | [1,151](/filings/0000950170-24-051879.md) | [1,150](/filings/0000950170-24-090144.md) | [1,247](/filings/0000950170-24-120026.md) | [1,316](/filings/0001193125-26-048139.md) | [1,208](/filings/0000950170-25-061624.md) | [1,209](/filings/0000950170-25-101235.md) | [1,501](/filings/0001193125-25-260515.md) | [1,498](/filings/0001193125-26-327567.md) | [1,413](/filings/0001193125-26-200630.md) | [1,327](/filings/0001193125-26-327567.md) | | Total liabilities | $m | [4,652](/filings/0000950170-23-058681.md) | [4,714](/filings/0000950170-25-019801.md) | [4,461](/filings/0000950170-24-051879.md) | [4,457](/filings/0000950170-24-090144.md) | [4,473](/filings/0000950170-24-120026.md) | [4,522](/filings/0001193125-26-048139.md) | [4,405](/filings/0000950170-25-061624.md) | [4,395](/filings/0000950170-25-101235.md) | [4,921](/filings/0001193125-25-260515.md) | [4,910](/filings/0001193125-26-327567.md) | [4,821](/filings/0001193125-26-200630.md) | [4,758](/filings/0001193125-26-327567.md) | | Long-term debt | $m | [2,402](/filings/0000950170-23-058681.md) | [2,202](/filings/0000950170-25-019801.md) | [2,203](/filings/0000950170-24-051879.md) | [2,208](/filings/0000950170-24-090144.md) | [2,208](/filings/0000950170-24-120026.md) | [2,205](/filings/0001193125-26-048139.md) | [2,205](/filings/0000950170-25-061624.md) | [2,206](/filings/0000950170-25-101235.md) | [2,205](/filings/0001193125-25-260515.md) | [2,205](/filings/0001193125-26-327567.md) | [2,206](/filings/0001193125-26-200630.md) | [2,206](/filings/0001193125-26-327567.md) | | Current portion of debt | $m | not reported | [200](/filings/0000950170-25-019801.md) | [0.0](/filings/0000950170-24-051879.md) | [0.0](/filings/0000950170-24-090144.md) | [0.0](/filings/0000950170-24-120026.md) | [0.0](/filings/0000950170-25-019801.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Short-term borrowings | $m | [3.8](/filings/0000950170-23-058681.md) | [3.9](/filings/0000950170-25-019801.md) | [4.0](/filings/0000950170-24-051879.md) | [6.1](/filings/0000950170-24-090144.md) | [3.4](/filings/0000950170-24-120026.md) | [0.0](/filings/0000950170-25-019801.md) | not reported | not reported | not reported | [0.0](/filings/0001193125-26-327567.md) | not reported | [49.9](/filings/0001193125-26-327567.md) | | Shareholders' equity | $m | [4,051](/filings/0000950170-24-120026.md) | [3,855](/filings/0001193125-26-048139.md) | [4,101](/filings/0001193125-25-260515.md) | [4,306](/filings/0001193125-25-260515.md) | [4,194](/filings/0001193125-25-260515.md) | [4,361](/filings/0001193125-26-327567.md) | [4,551](/filings/0001193125-26-327567.md) | [4,394](/filings/0001193125-26-327567.md) | [4,223](/filings/0001193125-25-260515.md) | [4,002](/filings/0001193125-26-327567.md) | [4,186](/filings/0001193125-26-327567.md) | [4,348](/filings/0001193125-26-327567.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Short-term borrowings: us-gaap:ShortTermBorrowings - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [286 d](/filings/0000950170-24-120026.md) | [236 d](/filings/0001193125-26-048139.md) | [263](/filings/0000950170-24-051879.md) | [237 d](/filings/0000950170-24-090144.md) | [364 d](/filings/0000950170-24-120026.md) | [292 d](/filings/0001193125-26-048139.md) | [186](/filings/0001193125-26-200630.md) | [231 d](/filings/0001193125-26-327567.md) | not reported | not reported | [175](/filings/0001193125-26-200630.md) | [287 d](/filings/0001193125-26-327567.md) | | Capital expenditure | $m | [58.3 d](/filings/0000950170-24-120026.md) | [102 d](/filings/0001193125-26-048139.md) | [46.3](/filings/0000950170-25-061624.md) | [30.3 d](/filings/0000950170-25-101235.md) | [48.6 d](/filings/0001193125-25-260515.md) | [54.6 d](/filings/0001193125-26-048139.md) | [16.5](/filings/0001193125-26-200630.md) | [22.5 d](/filings/0001193125-26-327567.md) | [28.2 d](/filings/0001193125-25-260515.md) | [55.2 d](/filings/0001193125-26-048139.md) | [31.9](/filings/0001193125-26-200630.md) | [29.9 d](/filings/0001193125-26-327567.md) | | Dividends paid | $m | [66.9 d](/filings/0000950170-24-120026.md) | [66.6 d](/filings/0001193125-26-048139.md) | [69.0](/filings/0000950170-25-061624.md) | [69.2 d](/filings/0000950170-25-101235.md) | [69.2 d](/filings/0001193125-25-260515.md) | [69.6 d](/filings/0001193125-26-048139.md) | [72.4](/filings/0001193125-26-200630.md) | [72.6 d](/filings/0001193125-26-327567.md) | [71.4 d](/filings/0001193125-25-260515.md) | [70.8 d](/filings/0001193125-26-048139.md) | [72.9](/filings/0001193125-26-200630.md) | [72.9 d](/filings/0001193125-26-327567.md) | | Share repurchases | $m | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001193125-25-260515.md) | [0.0 d](/filings/0001193125-26-048139.md) | not reported | not reported | [300 d](/filings/0001193125-25-260515.md) | [300 d](/filings/0001193125-26-048139.md) | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividends - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [246](/filings/0000950170-23-058681.md) | [247](/filings/0000950170-24-051879.md) | [248](/filings/0000950170-24-090144.md) | [249](/filings/0000950170-24-120026.md) | [246](/filings/0000950170-25-061624.md) | [247](/filings/0000950170-25-101235.md) | [245](/filings/0001193125-25-260515.md) | [248](/filings/0001193125-26-200630.md) | [246](/filings/0001193125-26-327567.md) | [243](/filings/0001193125-25-260515.md) | [238](/filings/0001193125-26-200630.md) | [238](/filings/0001193125-26-327567.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 237,203,907 at 2026-07-29, from the cover of the [10-Q filed 2026-07-31](/filings/0001193125-26-327567.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:21 ET. No prices; not investment advice.